Liver cancer diagnostic reagents Glypican-3 are successfully developed . Recently, the research group and Fuzhou new Biotechnology Development Co., Ltd. joint declaration GPC3 detection kit State Food and Drug Administration issued a Class III medical device registration certificate, will be officially in clinical application.
It is reported that researchers get GPC3 gene isolated from liver cDNA library, found its positive expression rate in liver cancer can arrive 80 percents, which is expected to diagnose earlier liver cancer with AFP . In addition, GPC3 expression is positive in benign tumors and others tumors . but the expression level gradually increased in malignant development of liver cancer, especially in a higher detection rate in patients with hepatocellular carcinoma AFP negative,shows clinical significance in prompting recurrence, metastasis and evaluation on surgical treatment .
significance.Based on a large sample analysis, the research team established standardized pathological diagnosis kit testing and evaluation program , developing a kind of GPC3 diagnostic elisa kit . The kit is completely the first independent elisa kit based on monoclonal antibody (http://www.bioabb.com/categories/Antibody/Monoclonal-Antibody/) , its clinical efficacy is superior to similar abroad products, this kind of kit has stronger specificity, more accurate cell positioning .
Wang Hongyang introduce that the kit is mainly used for liver pathological diagnosis and classification, especially in difficult cases of liver tumors, benign and malignant differential diagnosis,, this discovery play an important role in clinical treatment of malignant liver tumors and avoiding over-treatment of benign cases .